Mangalam Drugs Share Price Jump Analyzed

Mangalam Drugs and Organics’ stock price jumped significantly on Monday, hitting a 5% increase to ₹26.28 per share. This big rise happened because an investment firm, Kedia Securities, bought a large chunk of the company’s stock. The BSE Sensex, a major index of Indian stocks, also moved slightly upwards during this time.

Key Points

• Stock jumped 5% to ₹26.28 per share due to investment.
• Kedia Securities bought 1,37,794 shares at ₹24.15.
• Company’s market value is ₹41.6 crore, with a 52-week high of ₹129.9.
• Promoters hold 50.36% stake, with Vijay Kedia leading the investment.
• Company makes medicines & intermediates since 1977, with R&D facilities.
• Produces anti-malaria APIs and is a top producer globally.

Kedia Securities is the investment arm of Vijay Kedia, who focuses on buying stocks that are listed on stock exchanges and investing in new startups. They also invest in real estate. This news is important because it shows confidence in the company’s future.

Recently, Mangalam Drugs reported a loss for the last quarter (Q2). The company made ₹49.26 crore in sales, but also spent ₹57.01 crore. This means they had more expenses than income.

However, Mangalam Drugs has a long history – since 1977! They’ve become known for making important medicines used to fight malaria. They have a research lab that is recognized by the government.

This company is a leader in making these medicines, and it’s a big deal for India’s pharmaceutical industry. It demonstrates a shift in investor interest.

“A significant investment and a major jump in share price indicate potential future growth for Mangalam Drugs.”